陳韻晶 Yun-Ching Chen

傑出研究獎

國立清華大學
生物醫學工程研究所教授

學歷

  • 美國北卡大學教堂山分校分子藥劑學博士(2010)
  • 國立臺灣大學病理學碩士(2004)
  • 國立中山大學學士(2002)

經歷

  • 國立清華大學 生物醫學工程研究所教授(2020/8 ~ 迄今)
  • 國立清華大學 清華大學生物醫學科技研發中心主任(2022/1 ~ 迄今)
  • Journal of Controlled Release 副主編(2021/1 ~ 迄今)
個人勵志銘
Warn those who are idle, comfort the discouraged, help the weak, be patient with everyone.

開發藥物和基因遞送系統 克服對化療的抗藥性

I have had the privilege of contributing to the field of Pharmaceutical Sciences, and have been fortunate to work with exceptional mentors and collaborators throughout my career. After receiving my Ph.D. degree from the University of North Carolina at Chapel Hill in May 2010, I had the opportunity to complete postdoctoral training at the Department of Radiation Oncology at Harvard Medical School and Massachusetts General Hospital, where I was fortunate to work with Drs. Rakesh Jain and Dan Duda. During this time, I was able to contribute to the understanding of the important role of tumor stroma in immunosuppression, drug resistance, and cancer cell survival and metastasis. Since joining the faculty of National Tsing Hua University as a tenure-track Assistant Professor in 2013, I have been blessed with a talented and dedicated team of students and collaborators who have helped to drive our research forward. Our work has focused on developing various novel and effective formulations to deliver DNA, RNA and protein therapeutics and chemotherapy drugs for the treatment of cancer and inflammatory diseases such as renal fibrosis and liver cirrhosis. While I am proud of our progress, I recognize that there is still much work to be done in these areas. I am grateful for the recognition that our work has received, including publications in prestigious journals such as Journal of Controlled Release, Nature Nanotechnology, Nature Protocols, Advanced Materials, Gut, and Hepatology, as well as opportunities to serve in leadership roles such as Chair of the International Chapter Committee of the Controlled Release Society and Associate Editor of Journal of Controlled Release. I remain committed to advancing the field of pharmaceutical sciences and to supporting the next generation of researchers in this field.

傑出研究獎

得獎感言

I am deeply honored to have been recognized by the NSTC Award Committee. Our interdisciplinary team has been working diligently to develop novel therapeutic approaches to address the current clinical challenges of cancer treatment by modulating the immunosuppressive and desmoplastic tumor microenvironment. I am grateful to NTHU, NSTC, and NHRI for the generous support. I am also thankful to my students for their enthusiasm and dedication in research. I would like to express my sincere appreciation to Drs. Tsai-Te Lu at NTHU, Shu-Yi Lin and Kak-Shan Shia at NHRI, and many other colleagues and physicians for their invaluable assistance in enabling the team to conduct our research smoothly. As a scientist and a mother, I learn that balance is a myth. I must extend my utmost appreciation to my family for their unwavering support throughout my fantastic journey.